This facility was also inspected in February 2017 without any GMP observations. NSEBSEZydusLoading data…
ADD TO PORTFOLIO
ADD TO WATCHLIST
SHARE YOUR OULOOK
ChartsValuation & Peer ComparisonCommunity BuzzPEER COMPANIES New Delhi: Stock prices of Indian drug maker Zydus Cadila rose on Thursday after it said its plant in Gujarat cleared the US Food and Drug Administration’s inspection without any observations related to current Good Manufacturing Practices (cGMP).
The US FDA inspected Cadila’s Moraiya facility from August 31-September 7, 2017, confirmed the company in a filing to the BSE on Thursday afternoon.
“At the end of the inspection, no observation (483) is issued,” it stated.
This facility was also inspected in February 2017 without any GMP observations.
Cadila’s share price on BSE rose nearly 5% intra-day to Rs 519.90 apiece. Its stock closed at Rs 512.60, 3.41% up from the previous close, while the benchmark Sensex closed flat.